ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.134,94
-0,61%
S&P 500
6.040,53
-0,50%
US Dollar vs BRL
5,842
0,00%
Bitcoin
97.485,06
-3,15%
Brent Oil
76,385
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. NLS Pharmaceutics Ltd (NLSP)

  7. NLS Pharmaceutics Ltd (NLSP) Notícias

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLSP
DataHoraFonteTítuloCódigoCompanhia
31/01/202509:30PR Newswire (US)Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsNASDAQ:NLSPNLS Pharmaceutics Ltd
30/01/202509:30PR Newswire (US)NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingNASDAQ:NLSPNLS Pharmaceutics Ltd
28/01/202509:30PR Newswire (US)NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependenceNASDAQ:NLSPNLS Pharmaceutics Ltd
16/01/202511:32PR Newswire (US)Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSNASDAQ:NLSPNLS Pharmaceutics Ltd
08/01/202509:42PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share PriNASDAQ:NLSPNLS Pharmaceutics Ltd
30/12/202409:30PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerNASDAQ:NLSPNLS Pharmaceutics Ltd
04/12/202415:15PR Newswire (US)NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketNASDAQ:NLSPNLS Pharmaceutics Ltd
27/08/202417:01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:NLSPNLS Pharmaceutics Ltd
26/08/202417:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
15/07/202410:16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NLSPNLS Pharmaceutics Ltd
14/06/202309:38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
05/05/202317:37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
01/05/202317:31Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
24/02/202309:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/02/202308:10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
23/01/202308:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/01/202318:03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:NLSPNLS Pharmaceutics Ltd
21/12/202218:03Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NLSPNLS Pharmaceutics Ltd
16/12/202218:58Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
10/06/202217:44Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202213:15TipRanksBrookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
04/05/202215:25TipRanksBrookline Capital Markets Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/04/202217:49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/04/202209:18Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NLSPNLS Pharmaceutics Ltd
17/03/202211:36TipRanksMaxim Group Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
01/11/202109:31Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202109:00PR Newswire (US)NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021NASDAQ:NLSPNLS Pharmaceutics Ltd
28/05/202109:15PR Newswire (US)NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1NASDAQ:NLSPNLS Pharmaceutics Ltd
27/05/202118:29Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:NLSPNLS Pharmaceutics Ltd
18/05/202109:15PR Newswire (US)NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating NarcolepsyNASDAQ:NLSPNLS Pharmaceutics Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLSP

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
FICT3
Fictor Alimentos ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios